The KATHERINE phase III trial was initiated because we know that HER2-positive early breast cancer patients who receive neoadjuvant HER2-based chemotherapy and have residual invasive disease on surgical pathology have a worse prognosis than those who achieve a pathologic complete response [12]. This evidence concerns the gene ERBB2 and breast carcinoma.